Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 249

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial

Open access
Dührsen, Ulrich, Müller, Stefan, Hertenstein, Bernd, Thomssen, Henrike, Kotzerke, Jörg, Mesters, Rolf, Berdel, Wolfgang E., Franzius, Christiane, Kroschinsky, Frank, Weckesser, Matthias, Kofahl-Krause, Dorothea, Bengel, Frank M., Dürig, Jan, Matschke, Johannes, Schmitz, Christine, Pöppel, Thorsten, Ose, Claudia, Brinkmann, Marcus, La Rosée, Paul, Freesmeyer, Martin, Hertel, Andreas, Höffkes, Heinz-Gert, Behringer, Dirk, Prange-Krex, Gabriele, Wilop, Stefan, Krohn, Thomas, Holzinger, Jens, Griesshammer, Martin, Giagounidis, Aristoteles, Raghavachar, Aruna, Maschmeyer, Georg, Brink, Ingo, Bernhard, Helga, Haberkorn, Uwe, Gaska, Tobias, Kurch, Lars, van Assema, Daniëlle M.E., Klapper, Wolfram, Hoelzer, Dieter, Geworski, Lilli, Jöckel, Karl-Heinz, Scherag, André, Bockisch, Andreas, Rekowski, Jan, Hüttmann, Andreas, on behalf of the PETAL Trial Investigators·2018·Journal of Clinical Oncology

Abstract

Purpose: Interim positron emission tomography (PET) using the tracer, [18 F]fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin lymphomas. We assessed whether PET can guide therapy in patients who are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Patients and Methods: Newly diagnosed patients received two cycles of CHOP—plus rituximab (R-CHOP) in CD20-positive lymphomas—followed by a PET scan that was evaluated using the ΔSUV max method. PET-positive patients were randomly assigned to receive six additional cycles of R-CHOP or six blocks of an intensive Burkitt’s lymphoma protocol. PET-negative patients with CD20-positive lymphomas were randomly assigned or allocated to receive four additional cycles of R-CHOP or the same treatment with two additional doses rituximab. The primary end point was event-free survival time as assessed by log-rank test. Results: Interim PET was positive in 108 (12.5%) and negative in 754 (87.5%) of 862 patients treated, with statistically significant differences in event-free survival and overall survival. Among PET-positive patients, 52 were randomly assigned to R-CHOP and 56 to the Burkitt protocol, with 2-year event-free survival rates of 42.0% (95% CI, 28.2% to 55.2%) and 31.6% (95% CI, 19.3% to 44.6%), respectively (hazard ratio, 1.501 [95% CI, 0.896 to 2.514]; P = .1229). The Burkitt protocol produced significantly more toxicity. Of 754 PET-negative patients, 255 underwent random assignment (129 to R-CHOP and 126 to R-CHOP with additional rituximab). Event-free survival rates were 76.4% (95% CI, 68.0% to 82.8%) and 73.5% (95% CI, 64.8% to 80.4%), respectively (hazard ratio, 1.048 [95% CI, 0.684 to 1.606]; P = .8305). Outcome prediction by PET was independent of the International Prognostic Index. Results in diffuse large B-cell lymphoma were similar to those in the total group. Conclusion: Interim PET predicted survival in patients with aggressive lymphomas treated with R-CHOP. PET-based treatment intensification did not improve outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.76.8093

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 249

Metadata

Authors
Dührsen, U., Müller, S., Hertenstein, B., Thomssen, H., Kotzerke, J., Mesters, R., Berdel, W. E., Franzius, C., Kroschinsky, F., Weckesser, M., Kofahl-Krause, D., Bengel, F. M., Dürig, J., Matschke, J., Schmitz, C., Pöppel, T., Ose, C., Brinkmann, M., La Rosée, P., Freesmeyer, M., Hertel, A., Höffkes, H.-G., Behringer, D., Prange-Krex, G., Wilop, S., Krohn, T., Holzinger, J., Griesshammer, M., Giagounidis, A., Raghavachar, A., Maschmeyer, G., Brink, I., Bernhard, H., Haberkorn, U., Gaska, T., Kurch, L., van Assema, D. M. E., Klapper, W., Hoelzer, D., Geworski, L., Jöckel, K.-H., Scherag, A., Bockisch, A., Rekowski, J., Hüttmann, A., & on behalf of the PETAL Trial Investigators
Venue
Journal of Clinical Oncology
Published
2018-07-10
Volume
36
Issue
20
Pages
2024-2034
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2800320119
Cited by
249
References
1
FWCI
17.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. https://app.cochat.ai/papers/10.1200/jco.2017.76.8093
The paper
Dührsen, U., Müller, S., Hertenstein, B., Thomssen, H., Kotzerke, J., Mesters, R., Berdel, W. E., Franzius, C., Kroschinsky, F., Weckesser, M., Kofahl-Krause, D., Bengel, F. M., Dürig, J., Matschke, J., Schmitz, C., Pöppel, T., Ose, C., Brinkmann, M., La Rosée, P., . . . on behalf of the PETAL Trial Investigators. (2018). Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.8093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.